C. Queralt

发表

Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients.

R. Rosell, J. Sánchez, C. Camps, 2003, Clinical lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

M. Taron, M. Santarpia, M. Sánchez-Ronco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

Pedro Mendez, Jose Luis Mate, Rafael Rosell, 2005, Lung cancer.

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

V. Guillem, L. Paz-Ares, R. Rosell, 2010, European Respiratory Journal.

Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery

E. Felip, R. Rosell, M. Taron, 2004, Clinical Cancer Research.

Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.

E. Felip, R. Rosell, M. Taron, 2005, Clinical lung cancer.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

R. Rosell, M. Taron, M. Provencio, 2008 .

Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.

R. Rosell, M. Taron, M. Margelí, 2003, Cancer letters.

Serum DNA as a tool for cancer patient management.

C. Balañà, M. Taron, J. Ramírez, 2003, Roczniki Akademii Medycznej w Bialymstoku.

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Mayumi Ono, Jose Luis Mate, David Jablons, 2005, Clinical Cancer Research.

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

C. García-Girón, R. Rosell, M. Taron, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

R. Rosell, M. Taron, N. Reguart, 2007 .

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

D. Arango, V. Moreno, E. Musulen, 2019, Cancers.

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.

R. Rosell, M. Taron, C. Camps, 2010 .

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

H. Ditzel, F. de Marinis, R. Rosell, 2017, Journal of the National Cancer Institute.

Screening for epidermal growth factor receptor mutations in lung cancer.

Mariano Provencio, Miguel Angel Molina, Bartomeu Massuti, 2009, The New England journal of medicine.

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

E. Felip, R. Rosell, M. Taron, 2004, Human molecular genetics.

Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial

B. Klughammer, M. Taron, S. Y. Cajal, 2014, PloS one.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

Miguel Angel Molina, Bartomeu Massuti, Carlos Camps, 2010, Journal of Translational Medicine.

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

J. Mate, C. Sawyers, A. Ariza, 2011, Clinical Cancer Research.

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells

J. Mate, R. Rosell, M. Taron, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas

C. Balañà, R. Rosell, J. Ramírez, 2017, Journal of Neuro-Oncology.

Biomarkers in lung oncology.

R. Rosell, Jia Wei, Baorui Liu, 2010, Pulmonary pharmacology & therapeutics.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

R. Rosell, M. Taron, N. Reguart, 2014, Lung cancer.

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

J. Bosch-Barrera, R. Rosell, J. Ramírez, 2018, Oncotarget.

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations

R. Rosell, M. Taron, E. Monso, 2009, European Respiratory Journal.

Low RAP80 mRNA Expression Correlates with Shorter Survival in Sporadic High-Grade Serous Ovarian Carcinoma

J. Raduà, R. Rosell, J. Ramírez, 2017, The International journal of biological markers.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small‐Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

R. Rosell, M. Santarpia, J. Ramírez, 2017, Clinical lung cancer.

Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial.

M. Taron, B. Massuti, C. Camps, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

β-Tubulin mutational analysis: tantalizing findings

R. Rosell, M. Taron, C. Sarries, 2002 .

Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling.

M. Taron, M. Santarpia, S. Benlloch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Screening for epidermal growth factor receptor mutations in lung cancer.

L. Paz-Ares, R. Rosell, M. Taron, 2009, The New England journal of medicine.

9141 POSTER Phase l/ll Trial of Vorinostat (V) in Combination With Erlotinib (E) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (pts) With EGFR Mutations After Erlotinib Progression – the TARZO Trial (NCT00503971)

R. Rosell, N. Reguart, C. Rolfo, 2011 .